AI assistant
10x Genomics, Inc. — Director's Dealing 2021
Sep 25, 2021
31830_dirs_2021-09-24_0219a1db-e93f-44d5-b0fa-2c09a9f3b9c5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-09-23
Reporting Person: Kosaraju Sridhar (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-23 | Class A Common Stock | S | 400 | $157.7126 | Disposed | 8600 | Indirect |
| 2021-09-23 | Class A Common Stock | S | 1100 | $159.5245 | Disposed | 7500 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 3458 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust").
F2: This transaction was executed in multiple trades at prices ranging from $157.20 to $157.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: These shares are held by the Kosaraju Family Trust.
F4: This transaction was executed in multiple trades at prices ranging from $158.94 to $159.81. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.